UCB to acquire Candid Therapeutics for up to $2.2 billion - Stock Watch Index

UCB to acquire Candid Therapeutics for up to $2.2 billion

May 3, 2026

UCB to acquire Candid Therapeutics for up to $2.2 billion

Search

RECENT PRESS RELEASES

South Texas residents say SpaceX rocket testing has caused damage to homes

SWI Editorial Staff2026-05-03T16:07:00-07:00May 3, 2026|

Bitcoin rises 15% after Delphi Digital coordination shift

SWI Editorial Staff2026-05-03T16:03:14-07:00May 3, 2026|

NYSE to enable tokenized securities trading with blockchain integration

SWI Editorial Staff2026-05-03T15:46:11-07:00May 3, 2026|

Jim Cramer Says ‘Data Center’ Trade Is Going Mainstream

SWI Editorial Staff2026-05-03T15:31:31-07:00May 3, 2026|

Is Ethereum the generational wealth pick for real‑world crypto use?

SWI Editorial Staff2026-05-03T15:21:00-07:00May 3, 2026|

U.S. stock futures rise, oil falls as Trump touts new plan to partially reopen Strait of H

SWI Editorial Staff2026-05-03T15:19:00-07:00May 3, 2026|

Related Post